[BCRX] BioCryst Pharmaceuticals, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Biotechnology: Biological Products (No Diagnostic Substances)

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 6.99 Change: 0.59 (9.22%)
Ext. hours: Change: 0 (0%)

chart BCRX

Refresh chart

Strongest Trends Summary For BCRX

BCRX is in the medium-term down -23% below S&P in 3 weeks and down -75% below S&P in 1 year.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops small molecule pharmaceuticals that block key enzymes involved in the pathogenesis of diseases. The company integrates the disciplines of biology, crystallography, medicinal chemistry, and computer modeling to discover and develop drugs through the structure-guided drug design process. Its product candidates include peramivir, an intravenous neuraminidase inhibitor, which is approved for seasonal influenza in Japan and Korea, as well as to treat acute influenza; ulodesine, an oral purine nucleoside phosphorylase inhibitor, which has completed Phase II clinical trials for the treatment of gout; and forodesine, an oral purine nucleoside phosphorylase inhibitor that is in Phase II clinical trials for oncology. The company?s product candidates also comprise BCX4161, a Phase II oral serine protease inhibitor for hereditary angioedema (HAE); and BCX4430, a preclinical, RNA dependent-RNA polymerase inhibitor for treating Filovi

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS-0.63 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 365.62% Sales Growth - Q/Q25.34% P/E-8.81
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-38.67% ROE-78.01% ROI
Current Ratio1.32 Quick Ratio Long Term Debt/Equity Debt Ratio0.96
Gross Margin Operating Margin-311.12% Net Profit Margin-295.81% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities1.5 M Cash From Investing Activities-3.95 M Cash From Operating Activities-3.73 M Gross Profit6.81 M
Net Profit-15.16 M Operating Profit-14.43 M Total Assets129.87 M Total Current Assets81.37 M
Total Current Liabilities61.86 M Total Debt30 M Total Liabilities65.5 M Total Revenue6.83 M
Technical Data
High 52 week9.72 Low 52 week2.38 Last close2.5 Last change4.6%
RSI26.23 Average true range0.19 Beta1.24 Volume682.49 K
Simple moving average 20 days-9.49% Simple moving average 50 days-11.92% Simple moving average 200 days-56.01%
Performance Data
Performance Week0% Performance Month-20.38% Performance Quart-27.75% Performance Half-70.02%
Performance Year-64.34% Performance Year-to-date-69.02% Volatility daily4.73% Volatility weekly10.57%
Volatility monthly21.67% Volatility yearly75.06% Relative Volume907.2% Average Volume1.43 M
New High New Low

News

2019-10-03 07:00:00 | BioCryst Reports Inducement Grants Under NASDAQ Listing Rule 5635c4

2019-09-26 14:41:48 | Triangle drugmaker lands $14M purchase from federal government for flu treatment

2019-09-26 07:15:00 | U.S. Government Exercises Option for Additonal Rapivab® for Strategic National Stockpile

2019-09-24 16:15:00 | BioCryst Pharmaceuticals to Present at Cantor Global Healthcare Conference

2019-09-23 07:00:00 | BioCryst Appoints Helen Thackray, M.D., to Board of Directors

2019-09-10 07:44:48 | Triangle drugmaker looks to rebound with estimated $2 billion global market for new drug

2019-09-04 07:00:00 | BioCryst Reports Inducement Grants Under NASDAQ Listing Rule 5635c4

2019-09-03 16:15:00 | BioCryst to Present at H.C. Wainwright Global Investment Conference

2019-08-08 23:37:57 | Edited Transcript of BCRX earnings conference call or presentation 6-Aug-19 12:30pm GMT

2019-08-06 17:23:42 | Biocryst Pharmaceuticals Inc BCRX Q2 2019 Earnings Call Transcript

2019-08-06 09:45:01 | BioCryst Pharmaceuticals BCRX Reports Q2 Loss, Lags Revenue Estimates

2019-08-06 07:15:00 | BioCryst Reports Second Quarter 2019 Financial Results

2019-08-05 07:15:00 | BioCryst Reports Inducement Grants Under NASDAQ Listing Rule 5635C4

2019-07-30 10:38:02 | Earnings Preview: BioCryst Pharmaceuticals BCRX Q2 Earnings Expected to Decline

2019-07-23 07:15:00 | BioCryst to Report Second Quarter 2019 Financial Results on August 6

2019-07-03 07:15:00 | BioCryst Reports Inducement Grants Under NASDAQ Listing Rule 5635c4

2019-07-01 07:15:00 | BioCryst Appoints Megan Sniecinski Chief Business Officer

2019-06-27 16:15:00 | Biocryst Begins Enrollment of Phase 1 Trial of BCX9930, an Oral Factor D Inhibitor for Complement-Mediated Diseases

2019-06-11 20:20:32 | Is BioCryst Pharmaceuticals, Inc. BCRX A Good Stock To Buy?

2019-06-04 16:15:00 | BioCryst Reports Inducement Grants Under NASDAQ Listing Rule 5635c4

2019-05-31 07:00:00 | BioCryst to Present at Upcoming Investor Conferences

2019-05-30 14:03:00 | Here's Why BioCryst Pharmaceuticals Is Soaring Today

2019-05-22 07:34:00 | The Daily Biotech Pulse: Tocagen Tumbles, OncoSec Offering, Novartis Asthma Combo Drug Study

2019-05-21 16:40:00 | Why J.C. Penney, Mallinckrodt, and BioCryst Pharmaceuticals Slumped Today

2019-05-21 14:30:00 | In less than six hours today, this Durham company's stock has dropped 50 percent

2019-05-21 13:18:00 | Here's Why BioCryst Pharmaceuticals Collapsed Today

2019-05-21 10:54:38 | BioCryst Trades Sharply Lower Despite Acing Late-Stage Hereditary Angioedema Drug Trial

2019-05-21 07:00:00 | BioCryst’s Oral BCX7353 Meets Primary Endpoint in Phase 3 APeX-2 Trial

2019-05-14 08:46:12 | Do Options Traders Know Something About BioCryst Pharmaceuticals BCRX Stock We Don't?

2019-05-10 07:00:00 | BioCryst to Present at Bank of America Merrill Lynch Health Care Conference

2019-05-09 16:15:00 | BioCryst Completes Phase 1 Clinical Trial of Galidesivir

2019-05-08 17:38:40 | Edited Transcript of BCRX earnings conference call or presentation 8-May-19 12:30pm GMT

2019-05-08 14:23:48 | Biocryst Pharmaceuticals Inc BCRX Q1 2019 Earnings Call Transcript

2019-05-08 09:05:01 | BioCryst Pharmaceuticals BCRX Reports Q1 Loss, Tops Revenue Estimates

2019-05-08 07:59:35 | BioCryst: 1Q Earnings Snapshot

2019-05-08 07:00:00 | BioCryst Reports First Quarter 2019 Financial Results

2019-05-06 07:00:00 | BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635c4

2019-05-03 10:35:30 | Here’s What Hedge Funds Think About BioCryst Pharmaceuticals, Inc. BCRX

2019-05-01 10:33:02 | Analysts Estimate BioCryst Pharmaceuticals BCRX to Report a Decline in Earnings: What to Look Out for

2019-04-24 07:00:00 | BioCryst to Report First Quarter 2019 Financial Results on May 8

2019-04-04 09:36:01 | Implied Volatility Surging for BioCryst Pharmaceuticals BCRX Stock Options

2019-04-01 07:00:00 | BioCryst to Present at Upcoming Investor Conferences

2019-03-25 14:10:07 | BioCryst Pharmaceuticals, Inc. NASDAQ:BCRX: What Can We Expect From This High Growth Stock?

2019-03-06 08:20:00 | Report: Developing Opportunities within Sarepta Therapeutics, Sally Beauty, Danaher, Ellie Mae, BioCryst Pharmaceuticals, and Akcea Therapeutics — Future Expectations, Projections Moving into 2019

2019-03-04 14:19:15 | Edited Transcript of BCRX earnings conference call or presentation 4-Mar-19 1:30pm GMT

2019-03-04 11:29:59 | Biocryst Pharmaceuticals Inc BCRX Q4 2018 Earnings Conference Call Transcript

2019-03-04 07:02:00 | BioCryst Reports Fourth Quarter and Full Year 2018 Financial Results

2019-03-04 07:00:00 | BioCryst Advancing BCX9930, an Oral Factor D Inhibitor for Complement-Mediated Diseases, into Phase 1 Development

2019-03-03 09:41:52 | The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings, IPOs

2019-02-28 07:00:00 | BioCryst to Present at Barclays Global Healthcare Conference